EPISODE · Nov 10, 2015 · 25 MIN
Safety Elements of Cancer Immunotherapies: Immune Related Adverse Events
from PharmaTalkRadio · host Conference Forum
In this episode of Pharma Talk Radio, we feature medical oncologist, Dr Anna Pavlick, Director of the Melanoma Program at the NYU Cancer Institute on Safety Elements of Cancer Immunotherapies. Dr Pavlick originally gave this presentation in June 2015 at the IO360 conference. Her talk focuses on immune related adverse affects of immuno therapy. More specifically, she covers: • Identifying warning signs and low threshold for workup and treatment • Understanding “pseudoprogression” before response, delayed toxicities • Reporting and assessing adverse effects during clinical trial phases • How to predict safety concerns when moving from animal models to human trials We are pleased to bring this session to the public to help researchers, doctors, patients and care givers with some information on immune related adverse affects of immuno therapy. Please note that Dr Pavlick does occassionally refer to slides which are not included in the recording of this session. Anna Pavlick, DO, MD is the Director of the NYU Cancer Institute Melanoma Research Program. After finishing her studies at University of Medicine & Dentistry of New Jersey, School of Osteopathic Medicine, Dr Pavlick completed her residency in internal medicine and her fellowship in hematology/oncology at Memorial Sloan Kettering Cancer Center. In 1999, she went on to become the Director of Clinical Oncology at UMDNJ in New Jersey before coming to NYU. The next IO360 conference will take place February 2-3, 2016 at the New York Academy of Medicine in NYC. For more information, visit www.theconferenceforum.org.
What this episode covers
In this episode of Pharma Talk Radio, we feature medical oncologist, Dr Anna Pavlick, Director of the Melanoma Program at the NYU Cancer Institute on Safety Elements of Cancer Immunotherapies. Dr Pavlick originally gave this presentation in June 2015 at the IO360 conference. Her talk focuses on immune related adverse affects of immuno therapy. More specifically, she covers: • Identifying warning signs and low threshold for workup and treatment • Understanding “pseudoprogression” before response, delayed toxicities • Reporting and assessing adverse effects during clinical trial phases • How to predict safety concerns when moving from animal models to human trials We are pleased to bring this session to the public to help researchers, doctors, patients and care givers with some information on immune related adverse affects of immuno therapy. Please note that Dr Pavlick does occassionally refer to slides which are not included in the recording of this session. Anna Pavlick, DO, MD is the Director of the NYU Cancer Institute Melanoma Research Program. After finishing her studies at University of Medicine & Dentistry of New Jersey, School of Osteopathic Medicine, Dr Pavlick completed her residency in internal medicine and her fellowship in hematology/oncology at Memorial Sloan Kettering Cancer Center. In 1999, she went on to become the Director of Clinical Oncology at UMDNJ in New Jersey before coming to NYU. The next IO360 conference will take place February 2-3, 2016 at the New York Academy of Medicine in NYC. For more information, visit www.theconferenceforum.org.
NOW PLAYING
Safety Elements of Cancer Immunotherapies: Immune Related Adverse Events
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.